Merck & Co. and its partner Ridgeback Biotherapeutics sign an agreement with UNICEF to distribute up to 3 million courses of their COVID-19 antiviral pill molnupiravir to 100 low and middle-income countries in the first half of the year. (Thomson Reuters Foundation) COVID-19 drug developmentCOVID-19 pandemic link embed save